Determination of the starting dose in the first-in-human clinical trial of ERY974, a novel T cell-redirecting bispecific antibody targeting glypican-3, from MABEL and NOAEL approaches

Y. Sano, S. I. Komatsu, W. Frings,A. Kaneko, I. Takahiro, Y. Kayukawa,N. Ono,K. Sakata,T. Fujii,Y. Miyazaki,Y. Kinoshita,Y. Azuma,T. Tsunenari, S. Kishishita,M. Endo,J. Nezu

EUROPEAN JOURNAL OF CANCER(2018)

引用 0|浏览21
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要